Patients with synchronous (de novo) metastatic castration-sensitive prostate cancer appear to have worse survival outcomes and shorter time to develop castration resistance than patients with metachronous disease.
However, the impact of synchronous metastasis on outcomes in metastatic castration-resistant prostate cancer (mCRPC) setting is unknown in patients without prior exposure to androgen receptor pathway inhibitors (ARPIs). In this study, we assessed the impact of initial timing of metastasis (synchronous vs metachronous) on survival outcomes of patients with new-onset mCRPC in a real-world population treated with first-line abiraterone or enzalutamide.
Data were collected retrospectively from 323 patients with a confirmed diagnosis of mCRPC who received ARPIs as first-line therapy and had no prior exposure to ARPIs. The study endpoints were progression-free survival and overall survival (OS).
The results showed that median OS was significantly shorter in patients with synchronous disease than those with metachronous disease (26 vs 38.7 months, HR 1.42, 95% CI 1.09-1.86, P = .011). However, there was no difference in median progression-free survival.
The initial timing of metastasis remained an independent factor associated with shorter OS in the multivariable analysis. These hypothesis-generating data, after external validation, may have implications in patient counseling, prognostication, and design of future clinical trials in the new-onset mCRPC setting.
Urology practice. 2023 Oct 30 [Epub ahead of print]
Georges Gebrael, Nicolas Sayegh, Nishita Tripathi, Divyam Goel, Taylor McFarland, Hedyeh Ebrahimi, Blake Nordblad, Beverly Chigarira, Vinay Mathew Thomas, Kamal Kant Sahu, Haoran Li, Alexander Chehrazi-Raffle, Manish Kohli, Neeraj Agarwal, Umang Swami, Benjamin L Maughan
Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah., Division of Medical Oncology, Department of Internal Medicine, City of Hope, Duarte, California.